These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11994377)

  • 1. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
    Watts GF; Chan DC; Barrett PH; O'Neill FH; Thompson GR
    Int J Obes Relat Metab Disord; 2003 Jul; 27(7):862-5. PubMed ID: 12821974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
    Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA
    Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.
    Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
    Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
    J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
    Chan DC; Watts GF; Wang J; Hegele RA; van Bockxmeer FM; Barrett PH
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
    Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
    Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
    Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
    Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.